This paper is in the following e-collection/theme issue:

Early Results in Infodemiology and Infoveillance (72) Public (e)Health, Digital Epidemiology and Public Health Informatics (725) Cyberpharmacies (45) Substance Abuse (419) Opioid and Related Substance Misuse (147) Prevention and Health Promotion (986) Pharmacovigilance (134) Web-based and Mobile Health Interventions (3297) Harm Reduction Approaches (12)

Published on in Vol 8 (2024)

Preprints (earlier versions) of this paper are available at https://preprints.jmir.org/preprint/56755, first published .
Barriers to, and Facilitators of, Checking Drugs for Adulterants in the Era of Fentanyl and Xylazine: Qualitative Study

Barriers to, and Facilitators of, Checking Drugs for Adulterants in the Era of Fentanyl and Xylazine: Qualitative Study

Barriers to, and Facilitators of, Checking Drugs for Adulterants in the Era of Fentanyl and Xylazine: Qualitative Study

Authors of this article:

Ian David Aronson1, 2 Author Orcid Image ;   Mary-Andrée Ardouin-Guerrier1, 2 Author Orcid Image ;   Juan Esteban Baus1 Author Orcid Image ;   Alex S Bennett1 Author Orcid Image
Article Authors Cited by Tweetations (3) Metrics

Ian David Aronson   1, 2 , PhD ;   Mary-Andrée Ardouin-Guerrier   1, 2 , EdD ;   Juan Esteban Baus   1 , MS ;   Alex S Bennett   1 , PhD

1 School of Global Public Health, New York University, New York, NY, United States

2 Center for Technology-based Education and Community Health, NDRI-USA, New York, NY, United States

Corresponding Author:

  • Ian David Aronson, PhD
  • Center for Technology-based Education and Community Health
  • NDRI-USA
  • 31 W 34th St Suite 8006
  • New York, NY, 10001
  • United States
  • Phone: 1 212-845-4444
  • Email: aronson@ndri-usa.org